Vascular normalization in orthotopic glioblastoma following intravenous treatment with lipid-based nanoparticulate formulations of irinotecan or vincristine

Background Chemotherapy for glioblastoma (GBM) patients is compromised in part by poor perfusion in the tumor. The present study evaluates how treatment with liposomal formulation of irinotecan (Irinophore C[TM]), and other liposomal anticancer drugs, influence the tumor vasculature of GBM models gr...

Full description

Saved in:
Bibliographic Details
Published inBMC cancer Vol. 11; p. 124
Main Authors Verreault, Maite, Strutt, Dita, Masin, Dana, Anantha, Malathi, Yung, Andrew, Kozlowski, Piotr, Waterhouse, Dawn, Bally, Marcel B, Yapp, Donald T
Format Journal Article
LanguageEnglish
Published BioMed Central Ltd 08.04.2011
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Background Chemotherapy for glioblastoma (GBM) patients is compromised in part by poor perfusion in the tumor. The present study evaluates how treatment with liposomal formulation of irinotecan (Irinophore C[TM]), and other liposomal anticancer drugs, influence the tumor vasculature of GBM models grown either orthotopically or subcutaneously. Methods Liposomal vincristine (2 mg/kg), doxorubicin (Caelyx.sup.[R].sup.; 15 mg/kg) and irinotecan (Irinophore C[TM]; 25 mg/kg) were injected intravenously (i.v.; once weekly for 3 weeks) in Rag2M mice bearing U251MG tumors. Tumor blood vessel function was assessed using the marker Hoechst 33342 and by magnetic resonance imaging-measured changes in vascular permeability/flow (K.sub.trans ). Changes in CD31 staining density, basement membrane integrity, pericyte coverage, blood vessel diameter were also assessed. Results The three liposomal drugs inhibited tumor growth significantly compared to untreated control (p [less than] 0.05-0.001). The effects on the tumor vasculature were determined 7 days following the last drug dose. There was a 2-3 fold increase in the delivery of Hoechst 33342 observed in subcutaneous tumors (p [less than] 0.001). In contrast there was a 5-10 fold lower level of Hoechst 33342 delivery in the orthotopic model (p [less than] 0.01), with the greatest effect observed following treatment with Irinophore C. Following treatment with Irinophore C, there was a significant reduction in K.sub.trans in the orthotopic tumors (p [less than] 0.05). Conclusion The results are consistent with a partial restoration of the blood-brain barrier following treatment. Further, treatment with the selected liposomal drugs gave rise to blood vessels that were morphologically more mature and a vascular network that was more evenly distributed. Taken together the results suggest that treatment can lead to normalization of GBM blood vessel the structure and function. An in vitro assay designed to assess the effects of extended drug exposure on endothelial cells showed that selective cytotoxic activity against proliferating endothelial cells could explain the effects of liposomal formulations on the angiogenic tumor vasculature.
AbstractList Background Chemotherapy for glioblastoma (GBM) patients is compromised in part by poor perfusion in the tumor. The present study evaluates how treatment with liposomal formulation of irinotecan (Irinophore C[TM]), and other liposomal anticancer drugs, influence the tumor vasculature of GBM models grown either orthotopically or subcutaneously. Methods Liposomal vincristine (2 mg/kg), doxorubicin (Caelyx.sup.[R].sup.; 15 mg/kg) and irinotecan (Irinophore C[TM]; 25 mg/kg) were injected intravenously (i.v.; once weekly for 3 weeks) in Rag2M mice bearing U251MG tumors. Tumor blood vessel function was assessed using the marker Hoechst 33342 and by magnetic resonance imaging-measured changes in vascular permeability/flow (K.sub.trans ). Changes in CD31 staining density, basement membrane integrity, pericyte coverage, blood vessel diameter were also assessed. Results The three liposomal drugs inhibited tumor growth significantly compared to untreated control (p [less than] 0.05-0.001). The effects on the tumor vasculature were determined 7 days following the last drug dose. There was a 2-3 fold increase in the delivery of Hoechst 33342 observed in subcutaneous tumors (p [less than] 0.001). In contrast there was a 5-10 fold lower level of Hoechst 33342 delivery in the orthotopic model (p [less than] 0.01), with the greatest effect observed following treatment with Irinophore C. Following treatment with Irinophore C, there was a significant reduction in K.sub.trans in the orthotopic tumors (p [less than] 0.05). Conclusion The results are consistent with a partial restoration of the blood-brain barrier following treatment. Further, treatment with the selected liposomal drugs gave rise to blood vessels that were morphologically more mature and a vascular network that was more evenly distributed. Taken together the results suggest that treatment can lead to normalization of GBM blood vessel the structure and function. An in vitro assay designed to assess the effects of extended drug exposure on endothelial cells showed that selective cytotoxic activity against proliferating endothelial cells could explain the effects of liposomal formulations on the angiogenic tumor vasculature.
Chemotherapy for glioblastoma (GBM) patients is compromised in part by poor perfusion in the tumor. The present study evaluates how treatment with liposomal formulation of irinotecan (Irinophore C[TM]), and other liposomal anticancer drugs, influence the tumor vasculature of GBM models grown either orthotopically or subcutaneously. Liposomal vincristine (2 mg/kg), doxorubicin (Caelyx.sup.[R].sup.; 15 mg/kg) and irinotecan (Irinophore C[TM]; 25 mg/kg) were injected intravenously (i.v.; once weekly for 3 weeks) in Rag2M mice bearing U251MG tumors. Tumor blood vessel function was assessed using the marker Hoechst 33342 and by magnetic resonance imaging-measured changes in vascular permeability/flow (K.sub.trans ). Changes in CD31 staining density, basement membrane integrity, pericyte coverage, blood vessel diameter were also assessed. The three liposomal drugs inhibited tumor growth significantly compared to untreated control (p [less than] 0.05-0.001). The effects on the tumor vasculature were determined 7 days following the last drug dose. There was a 2-3 fold increase in the delivery of Hoechst 33342 observed in subcutaneous tumors (p [less than] 0.001). In contrast there was a 5-10 fold lower level of Hoechst 33342 delivery in the orthotopic model (p [less than] 0.01), with the greatest effect observed following treatment with Irinophore C. Following treatment with Irinophore C, there was a significant reduction in K.sub.trans in the orthotopic tumors (p [less than] 0.05). The results are consistent with a partial restoration of the blood-brain barrier following treatment. Further, treatment with the selected liposomal drugs gave rise to blood vessels that were morphologically more mature and a vascular network that was more evenly distributed. Taken together the results suggest that treatment can lead to normalization of GBM blood vessel the structure and function. An in vitro assay designed to assess the effects of extended drug exposure on endothelial cells showed that selective cytotoxic activity against proliferating endothelial cells could explain the effects of liposomal formulations on the angiogenic tumor vasculature.
Audience Academic
Author Yapp, Donald T
Strutt, Dita
Masin, Dana
Yung, Andrew
Anantha, Malathi
Bally, Marcel B
Kozlowski, Piotr
Verreault, Maite
Waterhouse, Dawn
Author_xml – sequence: 1
  fullname: Verreault, Maite
– sequence: 2
  fullname: Strutt, Dita
– sequence: 3
  fullname: Masin, Dana
– sequence: 4
  fullname: Anantha, Malathi
– sequence: 5
  fullname: Yung, Andrew
– sequence: 6
  fullname: Kozlowski, Piotr
– sequence: 7
  fullname: Waterhouse, Dawn
– sequence: 8
  fullname: Bally, Marcel B
– sequence: 9
  fullname: Yapp, Donald T
BookMark eNptUU1LxDAQDbKCrnr3GPBcTdo0bY8ifoHgRbwu03TSHUmTJckq-Fv8sXZRZA8yh3k83rzHY5Zs4YNHxs6luJSy1VdSNbIolWgKKQtZqgN2_Ect9vARW6b0JoRsWtEes69XSGbrIHIf4gSOPiFT8Jw8DzGvQw4bMnx0FHoHKYcJuA3OhQ_y4yzKEd7Rh23iOSLkCX3mH5TX3NGGhqKHhAP34MMGYqZdUMbZIE47NOckHiynSD5kNLDL5O_kTaSUyeMpO7TgEp797hP2cnf7cvNQPD3fP95cPxWjbrpCA5hOY429VbWFWg-m12WrETpTm0YLK8BU1QCiKWGwWqHoxFAZhSU2Ck11wi5-bEdwuCJvw1zLTJTM6rqslaqUaLtZdfmPap4BJzLzMyzN_N7BN2w2goQ
ContentType Journal Article
Copyright COPYRIGHT 2011 BioMed Central Ltd.
Copyright_xml – notice: COPYRIGHT 2011 BioMed Central Ltd.
DOI 10.1186/1471-2407-11-124
DatabaseTitleList

DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1471-2407
ExternalDocumentID A254434089
GroupedDBID ---
-A0
23N
2VQ
2WC
3V.
4.4
53G
5VS
6J9
6PF
7X7
88E
8FI
8FJ
AAFWJ
AAJSJ
AAWTL
ABDBF
ABUWG
ABVAZ
ACGFO
ACGFS
ACIHN
ACPRK
ACRMQ
ADBBV
ADINQ
ADRAZ
AEAQA
AENEX
AFGXO
AFKRA
AFNRJ
AFPKN
AHBYD
AHMBA
AHSBF
AHYZX
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AMTXH
AOIJS
BAPOH
BAWUL
BCNDV
BENPR
BFQNJ
BMC
BPHCQ
BVXVI
C1A
C24
C6C
CCPQU
CS3
DIK
DU5
E3Z
EAD
EAP
EAS
EBD
EBS
EJD
EMB
EMK
EMOBN
ESX
F5P
FYUFA
GROUPED_DOAJ
GX1
HMCUK
HYE
IAO
IHR
IHW
INH
INR
IPNFZ
ISR
ITC
KQ8
M1P
M48
M~E
O5R
O5S
OK1
P2P
PIMPY
PQQKQ
PROAC
PSQYO
RBZ
RIG
RNS
ROL
RPM
RSV
SBL
SOJ
SV3
TR2
TUS
U2A
UKHRP
W2D
WOQ
WOW
XSB
ID FETCH-LOGICAL-g679-6aac96e5ebf45fa56dcb6286ea9c5c760f0ac33da072adf64e090d3c4e2e74ec3
IEDL.DBID M48
ISSN 1471-2407
IngestDate Fri Feb 23 00:16:26 EST 2024
Fri Feb 02 04:28:29 EST 2024
IsPeerReviewed true
IsScholarly true
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-g679-6aac96e5ebf45fa56dcb6286ea9c5c760f0ac33da072adf64e090d3c4e2e74ec3
ParticipantIDs gale_infotracmisc_A254434089
gale_infotracacademiconefile_A254434089
PublicationCentury 2000
PublicationDate 20110408
PublicationDateYYYYMMDD 2011-04-08
PublicationDate_xml – month: 04
  year: 2011
  text: 20110408
  day: 08
PublicationDecade 2010
PublicationTitle BMC cancer
PublicationYear 2011
Publisher BioMed Central Ltd
Publisher_xml – name: BioMed Central Ltd
SSID ssj0017808
Score 1.9845791
Snippet Background Chemotherapy for glioblastoma (GBM) patients is compromised in part by poor perfusion in the tumor. The present study evaluates how treatment with...
Chemotherapy for glioblastoma (GBM) patients is compromised in part by poor perfusion in the tumor. The present study evaluates how treatment with liposomal...
SourceID gale
SourceType Aggregation Database
StartPage 124
SubjectTerms Blood-vessels
Care and treatment
Dosage and administration
Doxorubicin
Glioblastoma multiforme
Patient outcomes
Tumors
Vincristine
Title Vascular normalization in orthotopic glioblastoma following intravenous treatment with lipid-based nanoparticulate formulations of irinotecan or vincristine
Volume 11
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1LS8QwEA66gngRn7i6LjkInqrZbZq2B5FVFBHWg6iIF8lTCmu6duvrv_hjnanxBeKll0xamklmvsm8CNkCFS55ZnTUzyWPQOOzSCmDYWKJ7bHcJZZhNvLwTJxc8tPr5Po7PTos4ORP0w77SV1Wo52Xh9d9OPB7zYHPxG4PBCx6CVLMEQN9NU1m-liWCwP5-LdPIc2a_nRf1J9Oyz_eEOTzD01zvEDmA0Skgw-eLpIp65fI7DA4wZfJ21WIHqUeAecoZFLSwlN0wpR1OS40vRsVpQJoXJf3kjrgdvkMWgqIamw4hIVZ6VeQOcXbWDoqxoWJUK0Z6qUHa7pqKnMAGqUIbUOjrwktHS2qwmOBB4nfpE-F142w8HaFXBwfXRyeRKHJQnQn0jwSUupc2MQqxxMnE2G0wmxVK3Od6FQwx6SOYyNZ2pfGCW5Zzkysue3blFsdr5KWL71dI1Sl2mROMW6d4bkE5OlUjxmdNUanFW2yjYt6i7yEX9UyJADAbKxBdTvAamkxZ1neJp1flLDj9Y_h9f-HN8jcx8Uvj1jWIa26erSbgBxq1W0s7m6zLeB5fnDzDkUdx94
link.rule.ids 315,783,787,867,24332,27938,27939
linkProvider Scholars Portal
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Vascular+normalization+in+orthotopic+glioblastoma+following+intravenous+treatment+with+lipid-based+nanoparticulate+formulations+of+irinotecan+or+vincristine&rft.jtitle=BMC+cancer&rft.au=Verreault%2C+Maite&rft.au=Strutt%2C+Dita&rft.au=Masin%2C+Dana&rft.au=Anantha%2C+Malathi&rft.date=2011-04-08&rft.pub=BioMed+Central+Ltd&rft.issn=1471-2407&rft.eissn=1471-2407&rft.volume=11&rft.spage=124&rft_id=info:doi/10.1186%2F1471-2407-11-124&rft.externalDocID=A254434089
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1471-2407&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1471-2407&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1471-2407&client=summon